Skip to content
Enrolling by invitationNot applicable

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

NCT07737990 · PSI-GROUP · Joshua Rosenblat

Closed to entry
Status
Not accepting participants
Not applicable
Phase
65
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions. If group integration therapy is beneficial, then it has the potential to reduce resources required per patient for psilocybin-assisted psychotherapy, thereby increasing the cost-effectiveness of the treatment. However, no research has been done to understand if and how group therapy can support psychedelic integration for people with mood disorders. Therefore, the purpose of this study is to explore the benefit of psilocybin-assisted group therapy and to determine if psychedelic group integration therapy is acceptable to people who have received psychedelic-assisted therapy for mood disorders.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Impact on Behavioural Engagement with Integration

    Measured over From enrolment to the primary endpoint (Week 21)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Must be deemed to have capacity to provide informed consent; * Must sign and date the informed consent form; * Stated willingness to comply with all study procedures; * Stated willingness to comply with group integration requirements (i.e., maintaining confidentiality of other group members and group etiquette); * Stated willingness to commit to attending all group sessions. Of note, participants who miss a group session will not be penalized, provided they have communicated their anticipated or unanticipated absence with the study therapist(s); * Ability to read and communicate in English, such that their literacy and comprehension is sufficient for understanding the consent form, study questionnaires and group participation, as evaluated by study staff obtaining consent; * Met all the inclusion criteria and none of the exclusion criteria of either the PSI-1V2 or Psilo-BD clinical trials. * Completed the Primary Endpoint measures as part of the PSI-1V2 or Psilo-BD clinical trials. * Participants who are actively receiving therapy outside of this study are eligible to participate, provided the external therapy they are receiving is not psilocybin-assisted group integration psychotherapy. Exclusion Criteria: * Active suicidal ideation as determined by the C-SSRS and/or clinical interview (significant suicide risk is defined by suicidal ideation as endorsed by items 4 or 5 of the C-SSRS) or active suicidality requiring involuntary inpatient treatment or recent suicide attempts within the past month; * Withdrawal, dropout, loss to follow-up, or demonstrated significant study intervention non-compliance of either the PSI-1V2 or Psilo-BD clinical trials. * Any behaviors that, in the opinion of the investigator, may interfere with the group therapy model (e.g., participants in acute crisis, demonstrated resistance to the therapeutic process of the main clinical trials, etc.); * Participants who are actively receiving psilocybin-assisted group integration psychotherapy outside of the study.

Where

1 study site

FacilityCityRegionCountry
Toronto Western HospitalTorontoOntarioCanada

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07737990 on ClinicalTrials.gov →

Last updated in the registry 2026-07-30. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits